Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Angiostatin is a naturally occurring protein fragment derived from plasminogen that acts as an endogenous inhibitor of angiogenesis. It consists of multiple kringle domains and exerts its anti-angiogenic effects by binding to various proteins on endothelial cell surfaces, disrupting signaling pathways related to VEGF and nitric oxide, and modulating mitochondrial function. Its ability to inhibit tumor-induced neovascularization has led to clinical trials exploring its use in cancer therapy.
Inhibition of angiogenesis by blocking endothelial cell migration and proliferation, and by inducing apoptosis in endothelial cells; modulation of mitochondrial function
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Angiostatin.